טוען...
Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma
BACKGROUND: Cytotoxic chemotherapy (CC) is currently used in metastatic melanoma after patients have developed resistance to immune checkpoint inhibitors (ICI) and/or Mitogen‐Activated Protein Kinase inhibitors (MAPKi). We sought to evaluate if a previous treatment by ICI or MAPKi influences clinica...
שמור ב:
| הוצא לאור ב: | Cancer Med |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8124115/ https://ncbi.nlm.nih.gov/pubmed/33932099 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3760 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|